Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Meet Our Doctors
Dr. Jeffrey Weber
Melanoma Diagnosis Our Approach to Melanoma Treatment
Diagnosis
Melanoma Diagnosis
Surgery
Melanoma Surgery
Targeted Drugs & Immunotherapy
Melanoma Targeted Drugs and Immunotherapy
Radiation Therapy
Melanoma Radiation Therapy

Related News

Treatment Options for Later-Stage Melanoma
Read Story
Investigators Develop Novel Blood Tests for Tumor DNA
Read Story
How a Mentor–Mentee Team Found a New Understanding of Cancer
Read Story
Cancer Experts Share Updates in Immunology Advances
Read Story
Expert Discusses Taking Care of Your Skin This Summer
Read Story
Immunotherapy Provides New Options for Advanced Cancers
Read Story
Screening Guidelines for Skin Cancer & Melanoma, Explained
Read Story
Cancer Experts Discuss Immunotherapy’s Promises, Limitations
Read Story
Investigating the Molecular Basis of Metastatic Melanoma
Read Story

Clinical Trials and Research Studies

Phase 3

Adjuvant Therapy with Pembrolizumab versus Placebo in Resected Highrisk Stage II Melanoma: A Randomized Double-blind Phase 3 Study (KEYNOTE 716)

Learn More

Phase 1/2

A Phase 1/2 Open-Label Dose-Escalation Safety and Tolerability Study of NC318 in Subjects with Advanced or Metastatic Solid Tumors

Learn More

Phase 2

A randomized open-label phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma

Learn More

Phase 1/2

First In Human open-label dose-escalating trial with expansion cohorts to evaluate safety of Axl specific antibody drug conjugate (HuMax -AXL-ADC) in patients with solid tumors

Learn More
View All Related Clinical Trials (18)